CTRI/2013/01/003314Other未知
A randomized, double-blind, prospective, parallel study to assess efficacy and safety of Sugaheal®, a standardized extract of fenugreek seeds, in treatment naïve patients with type 2 diabetes mellitus
Indus Biotech Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- Other
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Treatment naïve patients of type 2 diabetes mellitus (defined as never receiving medical treatment for diabetes [insulin and/or oral antihyperglycemic medication] for > 6 months since original diagnosis, and no oral antihyperglycemic medication for more than 3 consecutive days or 7 nonconsecutive days during the 8 weeks prior to screening)
- •2.Fasting Plasma glucose (FPG) between 126 mg/dl and 250 mg/dl
- •3.Male or Female between 30 years to 65 years of age
- •4.Body Mass Index (BMI) between 18 kg/m2 to 30 kg/m2
- •5.HbA1c between 7% to 10% both inclusive
- •6.If on anti-hypertensive, lipid-lowering, or thyroid medications or hormone therapy, has been on constant dosage for at least 3 months prior to screening visit.
- •7.Patients those have voluntarily given written informed consent
- •8.Women with childbearing potential, willing to use effective contraceptive measures (other than oral contraceptive pills) such mechanical or barrier contraceptives, post- menopausal will be included.
- •9.In the opinion of the investigator, able to comply with the requirements of the protocol
- •10.Patients who received counseling on diet and exercise consistent with ADA recommendations
排除标准
- •Patients on hyperglycemic agent at screening visit
- •Type 1 diabetes patients
- •Females who are pregnant, lactating or planning to become pregnant
- •Known allergy to study medication
- •Patients with underline chronic disease of heart, liver, kidney, endocrine or neurological disease.
- •History of diabetic ketoacidosis or hyperosmolar nonketotic coma
- •Has a contagious, infectious disease
- •Currently taking herbals, dietary supplements, or medications, during the past 12 weeks that could profoundly affect blood glucose
- •Active malignancy.
- •AST / ALT more than or equal to 2.5 times the upper limit of normal laboratory value ( i.e. AST more than or equal to 100 and ALT more than or equal to 25 )
- •Serum creatinine more than or equal to1.5 mg/dl,
- •Any other conditions not eligible for the trial as per investigator or clinically significant abnormal laboratory values at screening visit.
- •Clinically significant abnormal red cell turnover, such as recent blood loss or transfusion or anemia [hemoglobin levels: less than 10 mg% (Male) and less than 9 mg% (Female)]
- •Patient of heart disease of Class III (marked limitation of any activity, the patient is comfortable only at rest) and Class IV (any physical activity brings discomfort and symptom occur at rest) as per New York Heart Association functional classification of heart diseases
- •Patients who smokes10 cigarettes per day
- •Alcohol intake more than 2 drinks/day
- •Subject participating simultaneously or 3 months prior to screening in any other clinical trial.
研究者
相似试验
招募中
1 期
To investigate efficacy, pharmacodynamics, and safety of BC 007 in participants with long COVIDEUCTR2022-003452-14-FIBerlin Cures GmbH114
招募中
1 期
To investigate efficacy, pharmacodynamics, and safety of BC 007 in participants with long COVIDlong CovidMedDRA version: 25.1Level: LLTClassification code 10087832Term: COVID-19 reboundSystem Organ Class: 10021881 - Infections and infestationsEUCTR2022-003452-14-DEBerlin Cures GmbH114
招募中
1 期
To investigate efficacy, pharmacodynamics, and safety of BC 007 in participants with long COVIDlong CovidMedDRA version: 25.1Level: LLTClassification code 10087832Term: COVID-19 reboundSystem Organ Class: 100000004862EUCTR2022-003452-14-ESBerlin Cures GmbH114
招募中
1 期
To investigate efficacy, pharmacodynamics, and safety of BC 007 in participants with long COVIDlong CovidMedDRA version: 25.1Level: LLTClassification code 10087832Term: COVID-19 reboundSystem Organ Class: 10021881 - Infections and infestationsEUCTR2022-003452-14-ATBerlin Cures GmbH114
已完成
3 期
A clinical study to assess the efficacy and safety of Vilanterol, Glycopyrronium and Fluticasone furoate Inhalation in patients with Chronic Obstructive Pulmonary DiseaseCTRI/2023/02/049362Zydus Healthcare Limited220